Log In
Print
BCIQ
Print
Print this Print this
 

pr-antiTNF (PRX-106)

  Manage Alerts
Collapse Summary General Information
Company Protalix BioTherapeutics Inc.
DescriptionRecombinant anti-tumor necrosis factor (TNF) fusion protein
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat immune-mediated diseases
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today